SAB Biotherapeutics (SABS)

• Market cap: $276M
• 1 day: 3.06%
• 5 days: -9.55%
• 1 month: 3.41%
• 3 months: -21.3%
• 6 months: -20.26%
• Year to date: -19.63%
• 1 year: -2.26%
• 5 years: -96.4%
• 10 years: -97.01%
• Sector: Healthcare
• Industry: Biotechnology

About: SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Employees: 86